Federal Register Notice: FDA’s Oncologic Drugs Advisory Committee will meet 7/20, from 8 a.m. to 3 p.m. at the Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD. The committee will discuss Genentech’s supplemental BLA for Avastin (bevacizumab), for (1) First-line treatment of a subgroup of women with HER2-negative breast cancer, in combination with the chemotherapy drug docetaxel; and (2) first-line treatment of HER2-negative metastatic breast cancer in combination with one of two classes of chemotherapy drugs, known as taxanes and anthracyclines, or with the chemotherapy drug, capecitabine. The committee will also consider the impact of the submitted studies on the conversion from accelerated to regular approval of the indication for the treatment, in combination with the chemotherapy drug paclitaxel, of patients who have not received chemotherapy for their locally recurrent or metastatic HER2 negative breast cancer. Contact Nicole Vesely, c/o Melanie Whelan, (301) 827-7001 before 6/8 and (301) 796-9001 after 6/8 or e-mail: nicole.vesely@fda.hhs.gov. To view this notice, click here.